Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Accumulated Expenses (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Accumulated Expenses for 5 consecutive years, with $434000.0 as the latest value for Q3 2020.

  • On a quarterly basis, Accumulated Expenses rose 119.19% to $434000.0 in Q3 2020 year-over-year; TTM through Sep 2020 was $434000.0, a 119.19% increase, with the full-year FY2019 number at $175000.0, down 98.66% from a year prior.
  • Accumulated Expenses was $434000.0 for Q3 2020 at Forte Biosciences, down from $6.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $13.1 million in Q4 2018 to a low of $65000.0 in Q1 2018.
  • A 5-year average of $4.4 million and a median of $1.6 million in 2017 define the central range for Accumulated Expenses.
  • Biggest YoY gain for Accumulated Expenses was 17069.23% in 2019; the steepest drop was 98.66% in 2019.
  • Forte Biosciences' Accumulated Expenses stood at $728000.0 in 2016, then skyrocketed by 1015.38% to $8.1 million in 2017, then surged by 61.26% to $13.1 million in 2018, then plummeted by 98.66% to $175000.0 in 2019, then surged by 148.0% to $434000.0 in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Accumulated Expenses are $434000.0 (Q3 2020), $6.0 million (Q1 2020), and $175000.0 (Q4 2019).